Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) Following 3Q Beat

November 4, 2016 7:38 AM EDT
Get Alerts IRWD Hot Sheet
Price: $14.76 --0%

Rating Summary:
    10 Buy, 11 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 10
Trade IRWD Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Mizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $20.00 (from $19.00), following the company's 3Q earnings report. IRWD reported revenues of $66.1M and a loss of ($0.18) vs. StreetAccount consensus of $59.8M and ($0.24).

Analyst Irina Koffler commented, "IRWD remains a calm refuge in our volatile sector and we are raising our PT to $20 after a strong 3Q:16 beat. We see the stock as meaningfully undervalued and less risky than the majority in our group."

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.

Shares of Ironwood Pharmaceuticals closed at $12.69 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Earnings, Irina Koffler

Add Your Comment